Elliot R D, Montgomery J A
J Med Chem. 1976 Oct;19(10):1186-91. doi: 10.1021/jm00232a004.
Two routes for the synthesis of 6-substtituted 8-azaguanosine analogues are described. 2,5,6-Triamino-4(3H)-pyrimidinethione (1) was converted by methylation, nitrosation, and acetylation to -n-acetyl-7-(methylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine (5). The reaction of 5 with 2,3,5-tri-O-acetyl-D-ribofuranosyl chloride gave a mixture of the 7-, 8-, and 9-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-8-azapurines 4a-c which was converted to 8-azaguanosine (7c) and the corresponding 7- and 8-substituted isomers 7a and 7b. 4a-c were also converted with NaOMe to 6-O-methyl-8-azaguanosine (8c) and to the corresponding 7- and 8-substituted isomers 8a and 8b. The preferred route, however, to 6-substituted 8-azaguanosine analogues is an unambigous synthesis through N2-acetyl-6-(benzylthio)-N4-(2,3-O-isopropylidene-beta-D-ribofuranosyl)-5-nitro-2,4-pyrimidinediamine (13), prepared from the reaction of the chloropyrimidine 10 with the aminoribose 11. Catalytic hydrogenation of 13 gave the aminopyrimidine 14, which was converted with nitrous acid to the nucleoside beta-20. Treatment of beta-20 with dilute acid gave 7-(benzylthio)-3-beta-D-ribofuranosyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine (19). Replacement of the benzylthio group of 19 with various nucleophilic reagents gave 8-aza-6-thioguanosine 17 and analogues 8c, 15, and 16. The thione 17 rearranges in aqueous solution to the thiasiazolopyrimidine 21. The parent [1,2,3]thiadiazolo[5,4-d]pyrimidine-5,7-diamine (24a) was prepared by nitrosation of the triaminopyrimidine (23a). Rearrangement of 24a in the presence of base gave a high yield of the thione 25a which could be rearranged with heat to 24a. Compounds 8a-c, 15-19, 24a, and 25 a were evaluated in the L1210 mouse leukemia screen- Only one compound, 8c, showed high cytotoxicity and borderline L1210 activity resulting from its en,ymatic conversion to 8-azaguanosine.
本文描述了两种合成6-取代8-氮杂鸟苷类似物的路线。2,5,6-三氨基-4(3H)-嘧啶硫酮(1)通过甲基化、亚硝化和乙酰化反应转化为N-乙酰基-7-(甲硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-5-胺(5)。5与2,3,5-三-O-乙酰基-D-核糖呋喃糖基氯反应得到7-、8-和9-(2,3,5-三-O-乙酰基-β-D-核糖呋喃糖基)-8-氮杂嘌呤4a-c的混合物,该混合物转化为8-氮杂鸟苷(7c)以及相应的7-和8-取代异构体7a和7b。4a-c也用甲醇钠转化为6-O-甲基-8-氮杂鸟苷(8c)以及相应的7-和8-取代异构体8a和8b。然而,合成6-取代8-氮杂鸟苷类似物的优选路线是通过由氯嘧啶10与氨基核糖11反应制备的N2-乙酰基-6-(苄硫基)-N4-(2,3-O-异亚丙基-β-D-核糖呋喃糖基)-5-硝基-2,4-嘧啶二胺(13)进行明确的合成。13的催化氢化得到氨基嘧啶14,其用亚硝酸转化为核苷β-20。用稀酸处理β-20得到7-(苄硫基)-3-β-D-核糖呋喃糖基-3H-1,2,3-三唑并[4,5-d]嘧啶-5-胺(19)。用各种亲核试剂取代19的苄硫基得到8-氮杂-6-硫鸟苷17以及类似物8c、15和16。硫酮17在水溶液中重排为噻二唑并嘧啶21。母体[1,2,3]噻二唑并[5,4-d]嘧啶-5,7-二胺(24a)通过三氨基嘧啶(23a)的亚硝化反应制备。24a在碱存在下重排得到高产率的硫酮25a,其可以加热重排为24a。化合物8a-c、15-19、24a和25a在L1210小鼠白血病筛选中进行了评估。只有一种化合物8c表现出高细胞毒性和临界L1210活性,这是由于其酶促转化为8-氮杂鸟苷所致。